32 results
8-K
MLYS
Mineralys Therapeutics, Inc.
14 Jun 24
Departure of Directors or Certain Officers
8:06am
404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended. The Board has determined that Dr. Gold is an independent director
8-K
EX-5.1
MLYS
Mineralys Therapeutics, Inc.
31 May 24
Financial Statements and Exhibits
4:06pm
of the Company as to the accuracy of such factual matters, in each case without independent verification thereof or other investigation. We have
8-K
MLYS
Mineralys Therapeutics, Inc.
22 May 24
Submission of Matters to a Vote of Security Holders
4:38pm
& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
For
Against
Abstain
Broker Non
424B5
0svv0d6fn425
11 Apr 24
Prospectus supplement for primary offering
4:35pm
DEF 14A
gfv4xn
9 Apr 24
Definitive proxy
7:15am
S-3/A
vx7vpisreqox9n41qrld
29 Mar 24
Shelf registration (amended)
4:44pm
S-3
EX-4.3
lqdbqazg
21 Mar 24
Shelf registration
7:30am
S-3
EX-5.1
psysc5dt ri5
21 Mar 24
Shelf registration
7:30am
S-3
EX-1.2
t1e561a14feob
21 Mar 24
Shelf registration
7:30am
S-3
EX-23.2
tq96z8a
21 Mar 24
Shelf registration
7:30am
S-3
i5u lt5hiahsrc3
21 Mar 24
Shelf registration
7:30am
8-K
EX-10.1
m0z9xt
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99
dv3 qbf8y
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
qcanztw
14 Sep 23
Departure of Directors or Certain Officers
4:11pm